Cargando…
In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
Introduction: [(227)Th]Th-3,2-HOPO-MSLN-mAb, a mesothelin (MSLN)-targeted thorium-227 therapeutic conjugate, is currently in phase I clinical trial; however, direct PET imaging using this conjugate is technically challenging. Thus, using the same MSLN antibody, we synthesized 3,2-HOPO and deferoxami...
Autores principales: | Roy, Jyoti, Jagoda, Elaine M., Basuli, Falguni, Vasalatiy, Olga, Phelps, Tim E., Wong, Karen, Ton, Anita T., Hagemann, Urs B., Cuthbertson, Alan S., Cole, Patricia E., Hassan, Raffit, Choyke, Peter L., Lin, Frank I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161658/ https://www.ncbi.nlm.nih.gov/pubmed/34014767 http://dx.doi.org/10.1089/cbr.2020.4492 |
Ejemplares similares
-
Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
por: Jagoda, Elaine M., et al.
Publicado: (2019) -
Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018) -
The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021) -
Alternative Chelator for (89)Zr Radiopharmaceuticals:
Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014) -
Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)